|
|
|
International Clinical Trials
|
ICT: It is essential that clinical trial logistics are carried
out in such a way as to optimise client investment. This involves
managing time- and temperature-sensitive products to deliver potentially
lifesaving treatments. How does World Courier ensure that drugs reach
their destinations unharmed?
Volker Kirchner: World
Courier is deeply involved with each shipment in the clinical trial
process, knowing that the successful outcome can directly affect a
patient’s health and life. Therefore, the safety, integrity and
successful delivery of every shipment is of paramount interest to us.
Before each project, we work closely with clients to gain a full
understanding of their material requirements. We then select a solution
comprising shipment routing, documentation and temperature-controlled
packaging, which ensures that the drugs arrive where they need to be,
when they need to be, and at the temperature they should be – without
fail.
Can you tell us more about the role of packaging in the cold chain, and what kind of solutions are currently on the market?
As
much of the material sent in the course of trials is
temperaturesensitive, packaging plays a critically important role in the
entire logistics process. There is a plenitude of different packaging
systems and solutions available – each with strengths and weaknesses in
specific situations – so selecting the best option for a certain drug is
a challenging matter, but one that the success or failure of a shipment
can easily hinge upon.
World Courier has maintained an
intensive overview of the multitude of different solutions available,
and even undertaken the task of creating its own temperature control
packaging solutions when none of sufficient performance existed on the
market. Our specialists are able to use their knowledge and overview of
the packaging to assess the best fit for a specific shipment or entire
project, required transport temperature, duration of transport,
infrastructure available at all points along the way, and possible risks
during transit, such as strikes and natural disasters.
With
this knowledge and experience, the question of whether to use an active
or passive container solution, a polystyrene box with dry ice or a dry
shipper, a lightweight composite box with water-based gel packs, or a
robust vacuum insulated shipper with high-quality phase change
materials, can be analysed and solved in a way that is the best answer
to the individual shipping challenge at hand.
How does World Courier guarantee that strong relationships with sponsors, CROs, laboratories and site personnel are maintained?
In
our experience, we have come to learn that communication is everything.
Offering standardised, ready-made solutions and trying to apply them to
very special shipments alone will not result in success. That’s why
in-depth communication is so essential for a successful transport
completion. Sponsors, CROs, laboratories and site personnel are all
aware of the facts about the product, origin, destination and regulatory
requirements which are critical, but only through communicating with
all stakeholders, and thereby gaining an intimate knowledge of the
project, can we understand enough to guarantee success. With that
success through communication, strong relationships can be forged. World
Courier places strict emphasis on trust.
How does your company ensure that organisations continue to have faith in the services you provide?
Put
simply, “the proof is in the pudding”. Claiming to be the most trusted
speciality logistics company in the world is not the beginning of the
path to success, but the outcome of it. When we partner with the
pharmaceutical industry to understand their logistical needs, and
create, innovate and test customtailored solutions to meet those demands
and ensure that every single detail is met to complete satisfaction,
the end result is invariably trust. That is the single most important
currency with which we are paid for our dedication and diligence, and it
is the currency that allows us to innovate even better and more
ambitious solutions to meet the logistical challenges of tomorrow.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
COPA-DATA USA Announces Office Move to Accommodate Accelerated Growth
COPA-DATA's New Facility in New Jersey Reinforces Innovative Culture and Commitment to Providing Industry-Leading Technology
COPA-DATA
USA, “We are excited to relocate to our new, larger office in New
Jersey,” commented Ray Giffen, Managing Director COPA-DATA USA. “This
move represents another significant milestone for our company. The new
office space better accommodates our growing team and enables us to hire
additional talent that will allow us to continue providing
industry-leading support and service.”
More info >> |
|
 |
White Papers |
 |
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
RSSL
Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >> |
|
|
